The current valuation score of Protalix Biotherapeutics Inc is 6.94, ranking 144 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 10.46, which is 536.38% below the recent high of 66.55 and 366.55% above the recent low of -27.88.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.